Literature DB >> 10962306

Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network.

P Finne1, R Finne, A Auvinen, H Juusela, J Aro, L Määttänen, M Hakama, S Rannikko, T L Tammela, U Stenman.   

Abstract

OBJECTIVES: To assess whether an artificial neural network (multilayer perceptron, MLP) and logistic regression (LR) could eliminate more false-positive prostate-specific antigen (PSA) results than the proportion of free PSA in a prostate cancer screening.
METHODS: MLP and LR models were constructed on the basis of data on total PSA, the proportion of free PSA, digital rectal examination (DRE), and prostate volume from 656 consecutive men (aged 55 to 67 years) with total serum PSA concentrations of 4 to 10 ng/mL in the randomized population-based prostate cancer screening study in Finland. The MLP and LR models were validated using the "leave-one-out" method.
RESULTS: Of the 656 men, 23% had prostate cancer and 77% had either normal prostatic histology or a benign disease. At a 95% sensitivity level, 19% of the false-positive PSA results could be eliminated by using the proportion of free PSA versus 24% with the LR model and 33% with the MLP model (P < 0.001). At 80% to 99% sensitivity levels, the accuracy of the MLP and LR models was significantly higher than that of the proportion of free PSA. At 89% to 99% sensitivities, the accuracy of the MLP was higher than that of LR (P </= 0.001).
CONCLUSIONS: At clinically relevant sensitivity levels, the MLP and LR models based on total PSA, the proportion of free PSA, DRE, and prostate volume could reduce the number of unnecessary biopsies significantly better than the proportion of free PSA alone in men with total PSA levels in the range 4 to 10 ng/mL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962306     DOI: 10.1016/s0090-4295(00)00672-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  21 in total

Review 1.  Artificial neural networks for predictive modeling in prostate cancer.

Authors:  Eduard J Gamito; E David Crawford
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

2.  Artificial neural networks for decision-making in urologic oncology.

Authors:  Theodore Anagnostou; Mesut Remzi; Bob Djavan
Journal:  Rev Urol       Date:  2003

3.  [New serum markers in prostate carcinoma and their application to artificial neural networks].

Authors:  C Stephan; K Jung; H Cammann; J Kramer; G Kristiansen; S A Loening; M Lein
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

Review 5.  Artificial neural networks and prostate cancer--tools for diagnosis and management.

Authors:  Xinhai Hu; Henning Cammann; Hellmuth-A Meyer; Kurt Miller; Klaus Jung; Carsten Stephan
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

Review 6.  [Value of biomarkers in urology].

Authors:  P J Goebell; B Keck; S Wach; B Wullich
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

Review 7.  Primer on machine learning: utilization of large data set analyses to individualize pain management.

Authors:  Parisa Rashidi; David A Edwards; Patrick J Tighe
Journal:  Curr Opin Anaesthesiol       Date:  2019-10       Impact factor: 2.706

8.  Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.

Authors:  Carsten Stephan; Chuanliang Xu; Henning Cammann; Markus Graefen; Alexander Haese; Hartwig Huland; Axel Semjonow; Eleftherios P Diamandis; Mesut Remzi; Bob Djavan; Mark F Wildhagen; Bert G Blijenberg; Patrik Finne; Ulf-Hakan Stenman; Klaus Jung; Hellmuth-Alexander Meyer
Journal:  World J Urol       Date:  2007-02-28       Impact factor: 4.226

Review 9.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

10.  [An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l].

Authors:  C Stephan; B Vogel; H Cammann; M Lein; V Klevecka; P Sinha; G Kristiansen; D Schnorr; K Jung; S A Loening
Journal:  Urologe A       Date:  2003-03-22       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.